Intravenous tranexamic acid decreases allogeneic transfusion requirements in periacetabular osteotomy

Andrew J. Bryan, Thomas L. Sanders, Robert T. Trousdale, Rafael J. Sierra

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Bernese (Ganz) periacetabular osteotomy is associated with significant blood loss and the need for perioperative transfusion. Tranexamic acid decreases blood loss and minimizes transfusion rates in total joint arthroplasty. However, no reports have described its use in patients undergoing Bernese periacetabular osteotomy. This study reports the use of intravenous tranexamic acid in these patients. The study included 137 patients (150 hips) who underwent isolated periacetabular osteotomy at a single institution between 2003 and 2014. Of these, 68 patients (75 hips) received intravenous tranexamic acid 1 g at the time of incision and 1 g at the time of closure. A group of 69 patients (75 hips) served as control subjects who underwent periacetabular osteotomy without administration of intravenous tranexamic acid. Thromboembolic disease was defined as deep venous thrombosis or pulmonary embolism occurring within 6 weeks of surgery. Outcomes measured included transfusion requirements, preand postoperative hemoglobin values, operative times, and thromboembolic disease rates. Aspirin was used as the thromboembolic prophylactic regimen in 95% of patients. The rate of allogeneic transfusion was 0 in the tranexamic acid group compared with 21% in the control group (P=.0001). No significant difference was found in the autologous cell salvage requirement (.96 vs 1.01; P=.43) or the thromboembolic disease rate between the tranexamic acid group and the control group (2.67% vs 1.33%; P=.31). The use of intravenous tranexamic acid led to a decreased transfusion requirement with no increased risk of thromboembolic disease in this contemporary cohort of patients undergoing periacetabular osteotomy.

Original languageEnglish (US)
Pages (from-to)44-48
Number of pages5
JournalOrthopedics
Volume39
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Tranexamic Acid
Osteotomy
Hip
Control Groups
Operative Time
Pulmonary Embolism
Venous Thrombosis
Arthroplasty
Intravenous Administration
Aspirin
Hemoglobins
Joints

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Intravenous tranexamic acid decreases allogeneic transfusion requirements in periacetabular osteotomy. / Bryan, Andrew J.; Sanders, Thomas L.; Trousdale, Robert T.; Sierra, Rafael J.

In: Orthopedics, Vol. 39, No. 1, 01.01.2016, p. 44-48.

Research output: Contribution to journalArticle

Bryan, Andrew J. ; Sanders, Thomas L. ; Trousdale, Robert T. ; Sierra, Rafael J. / Intravenous tranexamic acid decreases allogeneic transfusion requirements in periacetabular osteotomy. In: Orthopedics. 2016 ; Vol. 39, No. 1. pp. 44-48.
@article{592f36c775374f1eb8b07f34a85da822,
title = "Intravenous tranexamic acid decreases allogeneic transfusion requirements in periacetabular osteotomy",
abstract = "Bernese (Ganz) periacetabular osteotomy is associated with significant blood loss and the need for perioperative transfusion. Tranexamic acid decreases blood loss and minimizes transfusion rates in total joint arthroplasty. However, no reports have described its use in patients undergoing Bernese periacetabular osteotomy. This study reports the use of intravenous tranexamic acid in these patients. The study included 137 patients (150 hips) who underwent isolated periacetabular osteotomy at a single institution between 2003 and 2014. Of these, 68 patients (75 hips) received intravenous tranexamic acid 1 g at the time of incision and 1 g at the time of closure. A group of 69 patients (75 hips) served as control subjects who underwent periacetabular osteotomy without administration of intravenous tranexamic acid. Thromboembolic disease was defined as deep venous thrombosis or pulmonary embolism occurring within 6 weeks of surgery. Outcomes measured included transfusion requirements, preand postoperative hemoglobin values, operative times, and thromboembolic disease rates. Aspirin was used as the thromboembolic prophylactic regimen in 95{\%} of patients. The rate of allogeneic transfusion was 0 in the tranexamic acid group compared with 21{\%} in the control group (P=.0001). No significant difference was found in the autologous cell salvage requirement (.96 vs 1.01; P=.43) or the thromboembolic disease rate between the tranexamic acid group and the control group (2.67{\%} vs 1.33{\%}; P=.31). The use of intravenous tranexamic acid led to a decreased transfusion requirement with no increased risk of thromboembolic disease in this contemporary cohort of patients undergoing periacetabular osteotomy.",
author = "Bryan, {Andrew J.} and Sanders, {Thomas L.} and Trousdale, {Robert T.} and Sierra, {Rafael J.}",
year = "2016",
month = "1",
day = "1",
doi = "10.3928/01477447-20151222-10",
language = "English (US)",
volume = "39",
pages = "44--48",
journal = "Orthopedics",
issn = "0147-7447",
publisher = "Slack Incorporated",
number = "1",

}

TY - JOUR

T1 - Intravenous tranexamic acid decreases allogeneic transfusion requirements in periacetabular osteotomy

AU - Bryan, Andrew J.

AU - Sanders, Thomas L.

AU - Trousdale, Robert T.

AU - Sierra, Rafael J.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Bernese (Ganz) periacetabular osteotomy is associated with significant blood loss and the need for perioperative transfusion. Tranexamic acid decreases blood loss and minimizes transfusion rates in total joint arthroplasty. However, no reports have described its use in patients undergoing Bernese periacetabular osteotomy. This study reports the use of intravenous tranexamic acid in these patients. The study included 137 patients (150 hips) who underwent isolated periacetabular osteotomy at a single institution between 2003 and 2014. Of these, 68 patients (75 hips) received intravenous tranexamic acid 1 g at the time of incision and 1 g at the time of closure. A group of 69 patients (75 hips) served as control subjects who underwent periacetabular osteotomy without administration of intravenous tranexamic acid. Thromboembolic disease was defined as deep venous thrombosis or pulmonary embolism occurring within 6 weeks of surgery. Outcomes measured included transfusion requirements, preand postoperative hemoglobin values, operative times, and thromboembolic disease rates. Aspirin was used as the thromboembolic prophylactic regimen in 95% of patients. The rate of allogeneic transfusion was 0 in the tranexamic acid group compared with 21% in the control group (P=.0001). No significant difference was found in the autologous cell salvage requirement (.96 vs 1.01; P=.43) or the thromboembolic disease rate between the tranexamic acid group and the control group (2.67% vs 1.33%; P=.31). The use of intravenous tranexamic acid led to a decreased transfusion requirement with no increased risk of thromboembolic disease in this contemporary cohort of patients undergoing periacetabular osteotomy.

AB - Bernese (Ganz) periacetabular osteotomy is associated with significant blood loss and the need for perioperative transfusion. Tranexamic acid decreases blood loss and minimizes transfusion rates in total joint arthroplasty. However, no reports have described its use in patients undergoing Bernese periacetabular osteotomy. This study reports the use of intravenous tranexamic acid in these patients. The study included 137 patients (150 hips) who underwent isolated periacetabular osteotomy at a single institution between 2003 and 2014. Of these, 68 patients (75 hips) received intravenous tranexamic acid 1 g at the time of incision and 1 g at the time of closure. A group of 69 patients (75 hips) served as control subjects who underwent periacetabular osteotomy without administration of intravenous tranexamic acid. Thromboembolic disease was defined as deep venous thrombosis or pulmonary embolism occurring within 6 weeks of surgery. Outcomes measured included transfusion requirements, preand postoperative hemoglobin values, operative times, and thromboembolic disease rates. Aspirin was used as the thromboembolic prophylactic regimen in 95% of patients. The rate of allogeneic transfusion was 0 in the tranexamic acid group compared with 21% in the control group (P=.0001). No significant difference was found in the autologous cell salvage requirement (.96 vs 1.01; P=.43) or the thromboembolic disease rate between the tranexamic acid group and the control group (2.67% vs 1.33%; P=.31). The use of intravenous tranexamic acid led to a decreased transfusion requirement with no increased risk of thromboembolic disease in this contemporary cohort of patients undergoing periacetabular osteotomy.

UR - http://www.scopus.com/inward/record.url?scp=84959017114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959017114&partnerID=8YFLogxK

U2 - 10.3928/01477447-20151222-10

DO - 10.3928/01477447-20151222-10

M3 - Article

C2 - 26726988

AN - SCOPUS:84959017114

VL - 39

SP - 44

EP - 48

JO - Orthopedics

JF - Orthopedics

SN - 0147-7447

IS - 1

ER -